BEGIN:VCALENDAR PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN VERSION:2.0 BEGIN:VEVENT DESCRIPTION:Peptide therapies are rapidly becoming a disruptive modality\, led by Merck’s oral PCSK9 inhibitor and Johnson and Johnson’s IL23R\, wi th the hope to develop best-in-class drugs with improved chemistry\, form ulation and clinical efficacy.\n\nTo shine a light on the progress of thi s field\, the highly anticipated 3rd Peptide-Based Therapeutics Summit re turns to Boston as the industry’s only dedicated platform to turbocharge the next generation of peptide discoveries through development and toward s life-saving treatments.\n\nGathering industry leaders including Parabil is Medicines\, Circle Pharma\, Abbvie\, Merck\, Chugai Pharmaceuticals an d many more\, this is your premium forum to explore:\n\n- Novel computati onal tools- Optimize analytical assays- Formulating cell-specific deliver y methods- DMPK translatability towards clinical success of peptide thera pies\n\nJoin 100+ stakeholders from CEOs to Scientists in disciplines ran ging from peptide drug discovery R AND D\, medicinal chemistry\, pharmaco logy and formulation to accelerate this goldilocks modality from concept to commercialization.\n\nURLs:Tickets: \;https://go.evvnt.com/3373536 -2?pid=185 \;Brochure: \;https://go.evvnt.com/3373536-3?pid=185&n bsp\;\n\nDate and Time: Tue\, 28 Apr 2026 08:00 - Thu\, 30 Apr 2026 17:00 \n\nVenue details: Hilton Boston Logan Airport\, One Hotel Drive\, Boston \, Massachusetts\, 02128\, United States\n\nCategory: Conferences | Scien ce\, Health &\; Medicine | Pharmaceuticals\n\nPrices:Drug Developer - Conference + 2 Workshops: USD 4397.00\,Academic - Conference + 2 Workshop s: USD 3797.00\,Solution Provider - Conference + 2 Workshops: USD 5297.00 \,Drug Developer - Conference + 1 Workshop: USD 3748.00\,Academic - Confe rence + 1 Workshop: USD 3248.00\,Solution Provider - Conference + 1 Works hop: USD 4548.00\,Drug Developer - Conference Only: USD 3099.00\,Academic - Conference Only: USD 2699.00\,Solution Provider - Conference Only: USD 3799.00\n\n \;\n\nSpeakers: Pete Gough\, Head of Research\, Nimble T herapeutics\, Shelley Allen\, Project Director II\, Immuno-Pharmacology a nd Peptide Discovery\, Abbvie\, Annette Bak\, Head of Advanced Drug Deliv ery\, AstraZeneca\, Atsushi Matsuo\, Research Scientist\, Chugai Pharmace uticals\, Byungkook Qook Lee\, Research and Development Scientist (Resear ch Advisor)\, Eli Lilly\, Sumit Arora\, Senior Principal Scientist\, Oral Peptides\, Johnson and Johnson\, Maria Fawaz\, Associate Principal Scien tist\, DMPK\, Merck and Co\, Kaustav Biswas\, Senior Principal Scientist\ , Boston Discovery Chemistry\, Merck and Co\, Wen Jianzhong\, Senior Prin cipal Scientist and Group Lead\, Merck and Co\, Chen Liang\, Senior Scien tist II\, Novo Nordisk\, Olivera Grubisha\, Senior Group Leader\, In Vitr o Pharmacology\, UCB\, Phil Brandish\, Chief Scientific Officer\, AI Prot eins\, Christopher Brown\, Principal Investigator\, Agency for Science\, Technology and Research (A*STAR)\, Ajay Kshatriya\, Chief Executive Offic er\, Aizen Therapeutics\, Breena Fraga-Walton\, Senior Scientist\, Circle Pharma\, Florian Föger\, Chief Executive Officer\, Cyprumed\, David Earp \, President and Chief Executive Officer\, Circle Pharma\, Gilles Divita\ , Chief Executive Officer\, Divincell\, Michael Lipp\, Chief Technology O fficer\, Decoy Therapeutics\, Barbara Hibner\, Chief Scientific Officer\, Decoy Therapeutics\, Charles Johannes\, Founder\, President and Chief Sc ientist\, EPOC Scientific\, Soultan Al-Halifa\, Director R AND D\, Biopha rmaceutical Chemistry\, Feldan Therapeutics\, Hideki Tomioka\, Chief Scie ntific Officer\, Member of the Board\, Director of Research and Developme nt\, FunPep\, Bradley Pentelute\, Professor of Chemistry\, MIT\, Tomi Saw yer\, Chief Drug Hunter and President\, Maestro Therapeutics\, Kevin McDo nnell\, Senior Vice President\, Chemistry and Discovery\, Newco\, Justin Lawrie\, Senior Scientist\, Parabilis Medicines\, Immanuel Lerner\, Found er and Chief Executive Officer\, Pepticom\, Ved Srivastava\, Chief Techno logy Officer\, Perpetual Medicines\, David White\, Senior Vice President\ , Head of Drug Discovery\, ProteinQure\, Sam Hong\, Senior Director\, Hea d of Platform\, Rapafusyn Pharmaceuticals\, Barry Kappel\, Founder\, Pres ident and Chief Executive Officer\, Sapience Therapeutics\, David Brayden \, Professor of Advanced Drug Delivery\, University College Dublin\, Came ron Pye\, Chief Executive Officer\, Unnatural Products\, Joshua Schwocher t\, Chief Scientific Officer\, Unnatural Products\, Thomas von Erlach\, C o-Founder and Chief Scientific Officer\, Vivtex\, Peter Knauer\, Distingu ished Fellow\, CMC\, Xeris Biopharma\, Antoine Henninot\, Senior Director \, Drug Maker and Peptide Chemistry\, Curie.Bio\, Mi Cai\, Patent Attorne y\, Foley Hoag\, Kevin Carrick\, Senior Director Global Biologics\, US Ph armacopoeia\, Julie Zhang\, Team Lead\, Principal Scientist\, Global Biol ogics\, US Pharmacopoeia\, Alex Loftis\, Principal\, Vida Ventures\n DTEND:20260430T170000 DTSTAMP:20260512T214303Z DTSTART:20260428T080000 LOCATION:Hilton Boston Logan Airport\, One\, Hotel Drive\, Boston\, Massac husetts\, 02128\, SEQUENCE:0 SUMMARY:Peptide therapies are rapidly becoming a disruptive modality\, led by Merck’s oral PCSK9 inhibitor and Johnson and Johnson’s IL23R\, with t he hope to... UID:b8fdeb2d-62f0-4244-8439-693459c0d9d6 END:VEVENT END:VCALENDAR